PTGX (Protagonist Therapeutics, Inc.) Stock Financials & Earnings

PTGXProtagonist Therapeutics, Inc.

Mkt Cap$6B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$46M

Net Income (TTM)-$130M

EPS (TTM)-$2.05

Free Cash Flow (TTM)$58M

Gross Margin99.2%

Op. Margin-343.6%

Net Margin-282.8%

FCF Margin125.3%

P/S Ratio (TTM)134.9x

P/E Ratio (TTM)—

YoY Rev Growth-89.4%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$36M
Q2 23	$0	$0	-$42M
Q3 23	$0	$0	-$38M
Q4 23	$60M	$60M	$23M
Q1 24	$255M	$255M	$206M
Q2 24	$4M	$4M	-$39M
Q3 24	$5M	$5M	-$41M
Q4 24	$171M	$171M	$127M
Q1 25	$28M	$28M	-$19M
Q2 25	$6M	$6M	-$42M
Q3 25	$5M	$5M	-$46M
Q4 25	$7M	$7M	-$50M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$27M	$9M	—
Q2 23	$33M	$9M	—
Q3 23	$31M	$8M	—
Q4 23	$29M	$8M	—
Q1 24	$34M	$15M	—
Q2 24	$34M	$9M	—
Q3 24	$36M	$10M	—
Q4 24	$35M	$9M	—
Q1 25	$36M	$12M	—
Q2 25	$37M	$11M	—
Q3 25	$40M	$11M	—
Q4 25	$46M	—	$11M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$128M	$103M	$231M
Q2 23	$235M	$78M	$313M
Q3 23	$231M	$90M	$321M
Q4 23	$187M	$155M	$342M
Q1 24	$173M	$150M	$323M
Q2 24	$356M	$208M	$564M
Q3 24	$131M	$338M	$469M
Q4 24	$97M	$322M	$419M
Q1 25	$140M	$435M	$574M
Q2 25	$169M	$402M	$570M
Q3 25	$114M	$462M	$576M
Q4 25	$128M	$439M	$567M

Shares Outstanding

Revenue Per Employee

Revenue / Employee